Patents by Inventor Arthur Zelent

Arthur Zelent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Histone deacetylase 9
    Patent number: 7291492
    Abstract: The identification and cloning of histone deacetylase 9 (HDAC9) is disclosed, and in particular full length HCAC9 polypeptides and HDAC9 polypeptides which have deacetylase activity, and to nucleic acid molecules encoding these polypeptides. The uses of these polypeptides and nucleic acid molecules are disclosed, for example for screening for compounds that are capable of modulating HDAC9 biological activity.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: November 6, 2007
    Assignee: The Institute of Cancer Research
    Inventors: Arthur Zelent, Kevin Petrie, Fabien Guidez
  • Histone deacetylase 9
    Publication number: 20050130146
    Abstract: The identification and cloning of histone deacetylase 9 (HDAC9) is disclosed, and in particular full length HCAC9 polypeptides and HDAC9 polypeptides which have deacetylase activity, and to nucleic acid molecules encoding these polypeptides. The uses of these polypeptides and nucleic acid molecules are disclosed, for example for screening for compounds that are capable of modulating HDAC9 biological activity.
    Type: Application
    Filed: October 2, 2002
    Publication date: June 16, 2005
    Inventors: Arthur Zelent, Kevin Petrie, Fabien Guidez
  • Transcription therapy for cancers
    Patent number: 6262116
    Abstract: The present invention provides method of treating a neoplastic condition in an individual, comprising the step of administering to said individual a pharmacologically effective dose of a retinoic acid and/or an inhibitor of histone deacetylase. Also provided is a pharmaceutical composition, comprising a retinoic acid, an inhibitor of histone deacetylase and a pharmaceutically acceptable carrier. Further provided is a method of inducing terminal differentiation of tumor cells in a tumor in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a retinoic acid and/or an inhibitor of histone deacetylase.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: July 17, 2001
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Pier Paolo Pandolfi, Raymond P. Warrell, Jr., Arthur Zelent